Abstract：【Objective】To compare the effects of sertraline and paroxetine on neurotransmitter power and depression in patients with post-stroke depression.【Methods】A total of 140 patients with post-stroke depression were divided into two groups according to different treatment methods, with 70 cases in each group. Both groups were given conventional symptomatic treatment, while group A was also given sertraline treatment, while group B was given paroxetine treatment. The changes in Hamilton Depression Rating Scale-24 (HAMD) score, National Institutes of Health Stroke Scale (NIHSS) score, Barthel Index (BI) score, Asberg Antidepressant Side Effects Rating Scale (SERS) score before and after treatment were compared between the two groups. The changes in gamma-aminobutyric acid (GABA), acetylcholine (Ach), glutamate (Glu), norepinephrine (NE), interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α) levels before and after treatment, as well as the efficacy of the two groups, were also compared.【Results】The total effective rate of group A was 92.86% (65/70), which was higher than that of group B (80.00%,56/70) (P<0.05). After 4 weeks and 8 weeks of treatment, the HAMD scores of the two groups gradually decreased (P<0.05), and the HAMD score of group A was lower than that of group B (P<0.05). After 4 weeks and 8 weeks of treatment, the levels of GABA, Ach, Glu, NE, and BI scores gradually increased in both groups (P<0.05), while the GABA, Ach, Glu, NE, and BI scores in group A were higher than those in group B (P<0.05). After 4 weeks and 8 weeks of treatment, the IL-2, TNF-α, and NIHSS scores gradually decreased in both groups (P<0.05), and the IL-2, TNF-α, and NIHSS scores in group A were lower than those in group B (P<0.05). The SERS scores of group A were lower than those of group B after 4 weeks and 8 weeks of treatment (P<0.05).【Conclusion】Sertraline treatment for post-stroke depression can effectively improve patients' negative emotions, increase neurotransmitter power, reduce neural functional damage, and have high safety.
申贵玉黄焱, 谢清芳, 王能琨, 黄海东. 舍曲林与帕罗西汀治疗脑卒中后抑郁症对患者神经递质功率及抑郁情绪的影响比较[J]. 医学临床研究, 2025, 42(4): 638-641.
SHEN Guiyu, HUANG Yan, XIE Qingfang, et al. Comparison of the Effects of Sertraline and Paroxetine on Neurotransmitter Power and Depressive Mood in Patients with Post-Stroke Depression. JOURNAL OF CLINICAL RESEARCH, 2025, 42(4): 638-641.
[1] 尚晓峰,张莹,李虹,等.老年急性缺血性脑卒中患者衰弱与卒中后抑郁的相关性研究[J].中国全科医学,2020,23(30):3834-3838. [2] 张丽君,黄奕平.脑血管病常规药物联合SSRI类抗抑郁药物治疗脑卒中后抑郁的疗效分析[J].中西医结合心脑血管病杂志,2020,18(3):511-514. [3] 赵全,钱时德,焦冬生.帕罗西汀联合氟哌噻吨美利曲辛对脑卒中后抑郁及神经功能损伤的疗效[J].神经损伤与功能重建,2020,15(4):231-232. [4] 段天云,黄运红,刘丹萍.舍曲林用于老年脑卒中后抑郁的临床观察[J].中国医师杂志,2019,21(3):458-460. [5] 中国脑血管病防治指南编写委员会.中国脑血管病防治指南:试行版[M].北京:人民卫生出版社,2007:21-67. [6] 陈方彦.中国精神障碍分类与诊断标准(CCMD-3)[M].济南:山东科学技术出版社,2001:87-90. [7] 高政,刘启贵,姜潮.脑卒中急性期汉密尔顿抑郁评分的多因素分析[J].中国临床康复,2002,5(17):26-27. [8] 王大力,彭延波,邢磊,等.NIHSS评分在急性脑梗死患者中的应用与回归方程的建立[J].河北联合大学学报(医学版),2007,9(3):297-298. [9] 张世洪,吴波,谈颂.卒中登记研究中Barthel指数和改良的Rankin量表的适用性与相关性研究[J].中国循证医学杂志,2004,4(12):871-874. [10] 喻东山.药物副反应量表的因子重组[J].四川精神卫生,1998,3(3):54-56. [11] NATALIE H,LORRAINE K,LINDA M E, et al.The effects of relaxation training on depression and anxiety in people living with long-term neurological conditions[J].Disabil Rehabil,2020,42(15):2100-2105. [12] 苑杰,路月英,郭鑫, 等.舍曲林与阿米替林治疗中国人脑卒中后抑郁的疗效和安全性比较Meta分析[J].中国老年学杂志,2018,38(24):6017-6023. [13] MATTHIAS V,MANUEL C,WERHEID K.General self-efficacy as a driving factor of post-stroke depression:a longitudinal study[J].Neuropsychol Rehabil,2019,29(9):1426-1438. [14] TAMARA T,THOMAS L,LEONID C, et al.Longitudinal changes in activity participation in the first year post-stroke and association with depressive symptoms[J].Disabil Rehabil,2019,41(21):2548-2555.
2025, Vol. 42 
